Clinical Trial Update: Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TX05 with Herceptin in HER2-positive early breast cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stage Iiia Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• TX05

Snippet

Sponsor: Tanvex BioPharma USA, Inc. | Conditions: Breast Cancer, Breast Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2022-01-14